体外受精子宫内膜附加治疗:证据不足
该综述汇总了免疫治疗、子宫内膜搔刮、内膜容受性阵列、子宫动脉扩张及绒毛膜促性腺激素灌注等五种常见IVF附加治疗的证据。结果表明,没有强有力证据表明这些附加治疗有效或安全。许多附加治疗费用高昂,应在引入常规实践前进行大型随机对照试验和安全性评估。
要点
- 五种常见IVF子宫内膜附加治疗均缺乏强有力有效或安全的证据。
- 附加治疗费用高昂,可能消耗本可用于循证治疗或进一步IVF的资源。
- 引入常规实践前应进行大型随机对照试验和适当的安全性评估。
核心结论
- 没有强有力证据表明所综述的IVF子宫内膜附加治疗有效或安全。
研究设计与样本
- 综述纳入随机对照试验的系统评价和个体试验,涵盖五种附加治疗:免疫治疗、子宫内膜搔刮、内膜容受性阵列、子宫动脉扩张和绒毛膜促性腺激素灌注。
主要发现
- 所综述的五种附加治疗均缺乏强有力证据支持其有效或安全。
临床怎么用
- 许多IVF附加治疗费用高昂,消耗的资源可能更好地用于循证治疗或进一步IVF。
- 在引入常规实践前,应进行大型随机对照试验和适当的安全性评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The probability of live birth from an in vitro fertilization (IVF) cycle is modest. Many additional treatments (add-ons) are available which promise to improve the success of IVF. This review summarizes the current evidence for common IVF add-ons which are suggested to improve endometrial receptivity. Systematic reviews of randomized controlled trials and individual trials were included. Five add-ons were included: immune therapies, endometrial scratching, endometrial receptivity array, uterine artery vasodilation, and human chorionic gonadotropin instillation. The results suggest there is no robust evidence that these add-ons are effective or safe. Many IVF add-ons are costly, consuming precious resources which may be better spent on evidence-based treatments or further IVF. Large randomized controlled trials and appropriate safety assessment should be mandatory before the introduction of IVF add-ons into routine practice.
引用
- Lensen S, Shreeve N, Barnhart KT, et al. In vitro fertilization add-ons for the endometrium: it doesn't add-up. Fertil Steril. 2019. PMID: 31843098. doi:10.1016/j.fertnstert.2019.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。